XW10508 / XWPharma - LARVOL DELTA

An Open Label Safety and Efficacy Study of XW10508 Modified Release (MR) in Patients with Major Depressive Disorder (ANZCTR) - P2 | N=24 | Recruiting | Sponsor: XW Laboratories (Australia) Pty Ltd | Not yet recruiting ➔ Recruiting | Initiation date: Dec 2023

Enrollment open • Trial initiation date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

An Open Label Safety and Efficacy Study of XW10508 Modified Release (MR) in Patients with Major Depressive Disorder (ANZCTR) - P2 | N=24 | Not yet recruiting | Sponsor: XW Laboratories (Australia) Pty Ltd

New P2 trial • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry

Safety, Tolerability and Pharmacokinetics of XW10508 Immediate and Modified Release Formulations in Healthy Adults (clinicaltrials.gov) - P1 | N=84 | Completed | Sponsor: XWPharma | Recruiting ➔ Completed | Trial completion date: Dec 2021 ➔ Jun 2022 | Trial primary completion date: Dec 2021 ➔ Jun 2022

Trial completion • Trial completion date • Trial primary completion date

XWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain (GlobeNewswire) - "XWPharma Ltd. today announced dosing of subjects in its first-in-human study evaluating XW10508...once-daily therapy for the treatment of treatment-resistant depression and chronic pain....The Company anticipates initial results from this study in early 2022, which will allow for rapid progression into a Phase 2a test of safety and efficacy in patient cohorts."

P1 data • Trial status • CNS Disorders • Depression • Pain

Safety, Tolerability and Pharmacokinetics of XW10508 Immediate and Modified Release Formulations in Healthy Adults (clinicaltrials.gov) - P1; N=84; Recruiting; Sponsor: XWPharma

Clinical • New P1 trial